Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [921]
News [3774]
Articles [25]
Editorials [1]
Conferences [142]
elearning [0]
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of...
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
7 Oct 2019
IMspire170: New combination treatment for advanced melanoma
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
IMspire170: New combination treatment for advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine...
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
29 Sep 2019
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in...
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )
29 Sep 2019
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR...
Prof George Sledge - Stanford Health Care, Stanford, USA
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Comment: CDK4/6 inhibitors in advanced breast cancer
Prof Nadia Harbeck - University of Munich, Munich, Germany
Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
29 Sep 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation